{"name":"Yuhan Corporation","slug":"yuhan-corporation","ticker":"","exchange":"","domain":"","description":"Yuhan Corporation is a South Korean pharmaceutical and chemical company headquartered in Daebang-dong, Dongjak-gu, Seoul. It was established in 1926 by New Il-han and has been listed on the Korea Stock Exchange since 1962. Yuhan is one of the top Korean pharmaceutical companies, along with Celltrion, Samsung Biologics, GC Pharma, and Hanmi Pharmaceutical.","hq":"","founded":1926,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":12,"colorKey":"oncology","drugs":[{"name":"Anagre Cap.","genericName":"Anagre Cap.","slug":"anagre-cap","indication":"Other","status":"marketed"},{"name":"Aripezil® Tab.","genericName":"Aripezil® Tab.","slug":"aripezil-tab","indication":"Other","status":"marketed"},{"name":"Duowell®","genericName":"Duowell®","slug":"duowell","indication":"Other","status":"marketed"},{"name":"Monorova","genericName":"Monorova","slug":"monorova","indication":"Other","status":"marketed"},{"name":"Rosuvamibe","genericName":"Rosuvamibe","slug":"rosuvamibe","indication":"Other","status":"marketed"},{"name":"YH12852 IR 0.5mg","genericName":"YH12852 IR 0.5mg","slug":"yh12852-ir-0-5mg","indication":"Other","status":"phase_1"},{"name":"YH32364","genericName":"YH32364","slug":"yh32364","indication":"Other","status":"phase_1"},{"name":"YMC026","genericName":"YMC026","slug":"ymc026","indication":"Other","status":"marketed"},{"name":"Monorova® Tab","genericName":"Monorova® Tab","slug":"monorova-tab","indication":"Other","status":"marketed"},{"name":"Rosuvamibe® Tab","genericName":"Rosuvamibe® Tab","slug":"rosuvamibe-tab","indication":"Other","status":"marketed"},{"name":"YH12852 IR 0.1mg","genericName":"YH12852 IR 0.1mg","slug":"yh12852-ir-0-1mg","indication":"Other","status":"phase_1"},{"name":"YHR2501","genericName":"YHR2501","slug":"yhr2501","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"Anagre Cap.","genericName":"Anagre Cap.","slug":"anagre-cap","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Aripezil® Tab.","genericName":"Aripezil® Tab.","slug":"aripezil-tab","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Duowell®","genericName":"Duowell®","slug":"duowell","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Monorova","genericName":"Monorova","slug":"monorova","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Rosuvamibe","genericName":"Rosuvamibe","slug":"rosuvamibe","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"YH12852 IR 0.5mg","genericName":"YH12852 IR 0.5mg","slug":"yh12852-ir-0-5mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"YH32364","genericName":"YH32364","slug":"yh32364","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"YMC026","genericName":"YMC026","slug":"ymc026","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Monorova® Tab","genericName":"Monorova® Tab","slug":"monorova-tab","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Rosuvamibe® Tab","genericName":"Rosuvamibe® Tab","slug":"rosuvamibe-tab","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"YH12852 IR 0.1mg","genericName":"YH12852 IR 0.1mg","slug":"yh12852-ir-0-1mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"YHR2501","genericName":"YHR2501","slug":"yhr2501","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMia0FVX3lxTFBxQ29ERVhkMTRBWXFRZ19uQk80Z1d2T1ZNTFh4Z2k0V3FFWkV1OV9fVzBqSFFUaTk2NG5CU2hEOG1iaE1vbWF1NjlBemVEY3poNUIxMFBCVXhQMTJ3YUd4SnI5MEJ1SzdRRDRN?oc=5","date":"2026-04-08","type":"pipeline","source":"히트뉴스","summary":"Yuhan at 100: From Founding Philosophy to Global Innovation - 히트뉴스","headline":"Yuhan at 100: From Founding Philosophy to Global Innovation - 히트뉴스","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTFB3aVpDTjdMckNzLThVWjRHNUtjbmhtYUdYR0R2NTB1b3dlWER2WnAzNWdTQy1lbVFma0Z4dDZKUEdLaWpYOG42S1F0TUQ2NHlwckc5TWVJdHVzZnIxVldKMng5RU1wS3dXdzcteXpR0gFyQVVfeXFMUDJNck1Nb19hUncyUm5fdF9KcnMxSFFhV0psdEpzelhlVzJMeHRINHRBMjd1NXRqZjdnOGVKZTd3dHFGRElsOU1FcGotVEk1TnVwVVIzaHRDN2JUbElPbGE4WXFTdi0ybmZMd3Vnb0xvQzhn?oc=5","date":"2026-04-03","type":"pipeline","source":"koreabiomed.com","summary":"Yuhan pivots to targeted protein degradation to tackle ‘undruggable’ targets - koreabiomed.com","headline":"Yuhan pivots to targeted protein degradation to tackle ‘undruggable’ targets","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTE9jdkQ0QmtmUkRYSkpuV0w1SmVNOXhPbThBLXdaSmVPNl9PTEQ1VjFnak93ZDlOenBpc0tHWWUxaFlWWkU3WnR1T2poYVRFa0hwNWJKOTBlekJSUzBu?oc=5","date":"2026-03-23","type":"pipeline","source":"매일경제","summary":"Yuhan Corporation, which celebrates its 100th anniversary, will become a global pharmaceutical compa.. - 매일경제","headline":"Yuhan Corporation, which celebrates its 100th anniversary, will become a global pharmaceutical compa.. - 매일경제","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxPeWFSRnk5cnRrSG9WOGdXNFI0UThYZDhvR2hTbW1QLVhXNll4YkxBZm1Ha05vMlZIR211YkpnTGlLdUVoamRmS0ZuRHNfX2RjNWplRGZBVXJaVEdqbTNxY3I1VEc3bUJtMWxkeWpkZWlUS3lvSnJzS3laWllCcXVkYThFcElDTzN3TzZ4T2U1VzZqTVBqaEdRRFhLUHp4Y29VMHppS3BGdU1CbDMxNTJadWo1ZGc3cDdEdGU4a3l1WW00U0hzQ1RNSA?oc=5","date":"2026-03-22","type":"earnings","source":"AD HOC NEWS","summary":"Yuhan Corp stock faces pressure amid latest earnings miss and pipeline delays on Korea Exchange - AD HOC NEWS","headline":"Yuhan Corp stock faces pressure amid latest earnings miss and pipeline delays on Korea Exchange","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxNVU42VDlBck1FaVVtWGROeXNZTXpuTjNHX3d5UHFQQkVYWW9pT1Aydk9vNEo2T0dPWkp6Z2g1UXNoRDMyYU90SFdBOFV6LXJIWXBKM1h5WVZwRW9BWFNJYXV3ME9rWUNLaHZMWmNINHhhZnNOVlFWRDRkZUpGVjczRlo5MWU0YTAycGNBYjUweEc1RXgwMEpVSS1UTm15UC14QnNfT2ZMaHRRZzZnRHh5SUdEbVlRQWFKR0xmTHQ3UW4?oc=5","date":"2026-03-17","type":"pipeline","source":"AD HOC NEWS","summary":"Yuhan Corp Stock (ISIN: KR7000100008) Faces Headwinds Amid Korean Pharma Sector Slowdown - AD HOC NEWS","headline":"Yuhan Corp Stock (ISIN: KR7000100008) Faces Headwinds Amid Korean Pharma Sector Slowdown","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxPZ2xZZlktQXpHekpKLUJDbFhKMmR6UE5nMDc2RU5jOFh6aHNPYnhpTHByVkpvTUhiQldQdVcwUE51anpGSU9ocFJ2M2F3N3Q5aFF1MzF1WWgya296dExiNy1LLXltUUxtek1yWXBBVmdnamlpSjhnMFFsaFkwYVJseTdia0xKMUROSGhrUzhNR1EzTXNHRGEwamVUUzdMdTBXNFBfblRRU3I4Z25SemxjOGtrR3cxY1NSMy1hOA?oc=5","date":"2026-03-14","type":"pipeline","source":"AD HOC NEWS","summary":"Yuhan Corp Stock (ISIN: KR7000100008) Holds Steady Amid Korean Pharma Sector Shifts - AD HOC NEWS","headline":"Yuhan Corp Stock (ISIN: KR7000100008) Holds Steady Amid Korean Pharma Sector Shifts","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxPSjNNVUlkNmdDejFMSXBBb1hvMjZEM1k4SGhBaHVuVVF0clZHRFRoQ2tCN0t1VDZySF9EcU10aWR0S0dXeEF0T05ZWWJpYTc5eGtreEZOdFpQakk4SE1ZN0VTTzJUeTZvNlB5TzlKUDEySEhLcU91MmFLSG5NMC1zRDdCSnljMFpy?oc=5","date":"2026-02-19","type":"pipeline","source":"조선일보","summary":"Top Five Pharma Sales Jump 9%, Near 9 Trillion Won - 조선일보","headline":"Top Five Pharma Sales Jump 9%, Near 9 Trillion Won - 조선일보","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE9taEJZWmRZNHVBNENnODNYZ0JPSC1lTFAxT0dIMmhQbzl4QmFsd3hjVjdFcC1rMUJBQjBLVHJuVklqVVU5dkJ3Y011ZVVZX3BwcmQyMkFYSzhtWmgxYm5UTWxWbHJHYmNDT29Oa19n0gFyQVVfeXFMTmppT0JxaHRQSnZsSGFvNS16QlB5akZOWG1zYWxCWE93MzJyRVl6TlpHX2lRQUtwdjVIUVUtNEhhY2UyaGluMFZnSnotRlVQMmkzN3RrSnNGR3hwVkZ5Njd4bzNWTUlKb2RQU3RyZWMyZTZn?oc=5","date":"2026-02-19","type":"trial","source":"koreabiomed.com","summary":"Yuhan begins global phase 2 trial for allergy treatment, lesigercept - koreabiomed.com","headline":"Yuhan begins global phase 2 trial for allergy treatment, lesigercept","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxQcnpRQ05CUllYQjFiaTRKMC1zb2Ywa3RITzFnYWNHUWliYko3a1dleEJsZk45WFBoWjFMZERyYVktMmd0UW1rMDNKa1J5WGN3UUpETHRHanRYNW9RYVpVNHhpdmNfT3c0YnZ0S3pXWHZCN3E0cHVQeF9lTVM2NzIzbk1YX2E0Wmp2?oc=5","date":"2026-02-11","type":"earnings","source":"조선일보","summary":"Yuhan Corporation Posts 90% Profit Surge, 2.2 Trillion Won Sales - 조선일보","headline":"Yuhan Corporation Posts 90% Profit Surge, 2.2 Trillion Won Sales - 조선일보","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE9EUXl1NS1wTEg2NnFWUFJBWFRPbXJLV0hGSkR3TklGY0I2WEJBa1hiZ3JaejluekpySmEtNGs3SXFEMFhvREVtT25PeWY4eTdrM1B3Y2xaMS02bl9WWGp2WUl6MUNXVUlzSk16QjhR0gFyQVVfeXFMT3oxRXlaWndhUkRJVTNMUUh5Vk9hSjlKVGEteWJ3cFZpOE40UzJZdU9DenlzTmZkWGR5WFZ0VndNNmc1WklMaW5SYTNQT3U3UnlaSTRwOGhjR3BfTDBmYlhndzNUTDNaNjVRX3N5UVB3MUlR?oc=5","date":"2025-09-12","type":"pipeline","source":"koreabiomed.com","summary":"Yuhan R&D chief steps down, leaving gap after Leclaza success - koreabiomed.com","headline":"Yuhan R&D chief steps down, leaving gap after Leclaza success","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTFBFNnNQYXpjTWVkR2Q1QzFZa0pfclUzcFYyLUU0ajM2MTQ1M2FrV3d3QU1saWdJcWZ0d3MtWm1FeVVJeC1UbnZqQl9kX2FhRUs5RGF0bXlPWFR6ZEhlVjhMZVRidDRpcUJWY0txTlJ3?oc=5","date":"2025-08-18","type":"pipeline","source":"KED Global","summary":"Yuhan’s lung cancer drug eyes blockbuster sales by 2027 - KED Global","headline":"Yuhan’s lung cancer drug eyes blockbuster sales by 2027","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTFBpVW52emlrWTRBUlY0OV9wejhhNmx1VDZCYmEybmtadGQ4UVFCZlN5ejFIbTJfNXFiTXJ6WVh1VmlONWI4a3p6anV0YjlscVl3cWd5czNQNlU5QTh5S2JjYmxJR1hnNDFObmN4Qi1n0gFyQVVfeXFMTkdyRWUzQWVtZzlxdEhVanV3dFFJV0ZxdGZHRm5NSDlvSVp0bWdpOUhvMENUbnZuWFlLOUdubzJHRDZMOXF3OERJN1ZNc1dMVWM0RFBFUHlocW43QkZlbXhBNXNwMHJSZ1ZwTjFBenhMMHJ3?oc=5","date":"2025-07-11","type":"pipeline","source":"koreabiomed.com","summary":"Yuhan expands obesity pipeline with next-gen drugs, reformulated therapies - koreabiomed.com","headline":"Yuhan expands obesity pipeline with next-gen drugs, reformulated therapies","sentiment":"neutral"}],"patents":[],"drugCount":12,"phaseCounts":{"marketed":8,"phase_1":4},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}